EBR Systems (EBR) investor relations material

Executive summary

• Achieved key 2025 milestones, including FDA approval, early market release, and strong commercial momentum in Q1 2026, with case volumes more than doubling from Q4 2025.

• Successfully implanted the WISE System in 41 commercial patients during Q1 2026, reaching 71 total implants and validating the business thesis and large TAM.

• No direct competitors; product is complementary to existing technologies and gaining traction with major hospital systems.

• Expanded physician training, site readiness, and engagement, supporting broader adoption and positive clinical feedback.

• Advanced clinical initiatives, including further enrollment in post-approval and feasibility studies.

Financial highlights

• Q1 revenue reached nearly $2.4 million, up from zero in the same quarter last year, with preliminary unaudited Q1 2026 revenue expected between US$2.25M and US$2.36M.

• Gross profit percentage is volatile due to previously expensed inventory; normalization expected by late 2026 or 2027.

• Operating expenses increased as planned, driven by investments in sales and manufacturing, with some one-time payments in Q1.

• $2.5 million outflow for leasehold improvements will be reimbursed in Q2, resulting in a favorable impact next quarter.

• Revenue figures are subject to quarter-end closing adjustments and audit review.

Outlook and guidance

• Expect continued quarter-over-quarter revenue growth, driven by expanding sales force, hospital adoption, and disciplined execution.

• Focus remains on scaling the business, investing ahead of revenue, and building a foundation for broader adoption.

• Limited market release will transition to full commercialization once onboarding and productivity metrics are reproducible.

• Management expresses confidence in continued commercial and clinical progress.